Synonym
KN-92 HCl; KN 92 HCl; KN92 HCl; KN-92 hydrochloride
IUPAC/Chemical Name
(E)-N-(2-(((3-(4-chlorophenyl)allyl)(methyl)amino)methyl)phenyl)-4-methoxybenzenesulfonamide hydrochloride
InChi Key
SHDNWBMPAAXAHM-IPZCTEOASA-N
InChi Code
InChI=1S/C24H25ClN2O3S.ClH/c1-27(17-5-6-19-9-11-21(25)12-10-19)18-20-7-3-4-8-24(20)26-31(28,29)23-15-13-22(30-2)14-16-23;/h3-16,26H,17-18H2,1-2H3;1H/b6-5+;
SMILES Code
O=S(C1=CC=C(OC)C=C1)(NC2=CC=CC=C2CN(C/C=C/C3=CC=C(Cl)C=C3)C)=O.[H]Cl
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
KN-92 hydrochloride is an inactive derivative of KN-93, without CaM kinase inhibitory activity.
In vitro activity:
However, KN-92, an inactive derivative of KN-93, did not inhibit cell proliferation effectively. Moreover, analysis of cell cycle regulator expression revealed that KN-93 rather than KN-92 reduced the expression of p53 and p21.
Reference: World J Gastroenterol. 2007 Mar 7;13(9):1445-8. https://pubmed.ncbi.nlm.nih.gov/17457979/
In vivo activity:
KN-93 treatment preserved rat normal myocyte contraction, relaxation, [Ca2+]iT, and β-adrenergic reserve, whereas KN-92 treatment failed to improve LV and myocyte function, and plasma norepinephrine remained high in CHF.
Reference: J Pharmacol Exp Ther. 2021 Jun;377(3):316-325. https://pubmed.ncbi.nlm.nih.gov/33722881/
|
Solvent |
mg/mL |
mM |
comments |
| Solubility |
| DMF |
10.0 |
20.27 |
|
| DMSO |
30.0 |
60.80 |
|
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
493.44
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. An P, Zhu JY, Yang Y, Lv P, Tian YH, Chen MK, Luo HS. KN-93, a specific inhibitor of CaMKII inhibits human hepatic stellate cell proliferation in vitro. World J Gastroenterol. 2007 Mar 7;13(9):1445-8. doi: 10.3748/wjg.v13.i9.1445. PMID: 17457979; PMCID: PMC4146932.
2. Smyth JT, Abbott AL, Lee B, Sienaert I, Kasri NN, De Smedt H, Ducibella T, Missiaen L, Parys JB, Fissore RA. Inhibition of the inositol trisphosphate receptor of mouse eggs and A7r5 cells by KN-93 via a mechanism unrelated to Ca2+/calmodulin-dependent protein kinase II antagonism. J Biol Chem. 2002 Sep 20;277(38):35061-70. doi: 10.1074/jbc.M202928200. Epub 2002 Jul 16. PMID: 12121980.
3. Liu Y, Shao Q, Cheng HJ, Li T, Zhang X, Callahan MF, Herrington D, Kitzman D, Zhao D, Cheng CP. Chronic Ca2+/Calmodulin-Dependent Protein Kinase II Inhibition Rescues Advanced Heart Failure. J Pharmacol Exp Ther. 2021 Jun;377(3):316-325. doi: 10.1124/jpet.120.000361. Epub 2021 Mar 15. PMID: 33722881; PMCID: PMC8140392.
4. Kong L, Xiong F, Sun N, Xu C, Chen Y, Yang J, Su X. CaMKIIδ inhibition protects against myocardial ischemia/reperfusion injury: Role of Beclin-1-dependent autophagy. Eur J Pharmacol. 2020 Nov 5;886:173539. doi: 10.1016/j.ejphar.2020.173539. Epub 2020 Sep 9. PMID: 32918874.
In vitro protocol:
1. An P, Zhu JY, Yang Y, Lv P, Tian YH, Chen MK, Luo HS. KN-93, a specific inhibitor of CaMKII inhibits human hepatic stellate cell proliferation in vitro. World J Gastroenterol. 2007 Mar 7;13(9):1445-8. doi: 10.3748/wjg.v13.i9.1445. PMID: 17457979; PMCID: PMC4146932.
2. Smyth JT, Abbott AL, Lee B, Sienaert I, Kasri NN, De Smedt H, Ducibella T, Missiaen L, Parys JB, Fissore RA. Inhibition of the inositol trisphosphate receptor of mouse eggs and A7r5 cells by KN-93 via a mechanism unrelated to Ca2+/calmodulin-dependent protein kinase II antagonism. J Biol Chem. 2002 Sep 20;277(38):35061-70. doi: 10.1074/jbc.M202928200. Epub 2002 Jul 16. PMID: 12121980.
In vivo protocol:
1. Liu Y, Shao Q, Cheng HJ, Li T, Zhang X, Callahan MF, Herrington D, Kitzman D, Zhao D, Cheng CP. Chronic Ca2+/Calmodulin-Dependent Protein Kinase II Inhibition Rescues Advanced Heart Failure. J Pharmacol Exp Ther. 2021 Jun;377(3):316-325. doi: 10.1124/jpet.120.000361. Epub 2021 Mar 15. PMID: 33722881; PMCID: PMC8140392.
2. Kong L, Xiong F, Sun N, Xu C, Chen Y, Yang J, Su X. CaMKIIδ inhibition protects against myocardial ischemia/reperfusion injury: Role of Beclin-1-dependent autophagy. Eur J Pharmacol. 2020 Nov 5;886:173539. doi: 10.1016/j.ejphar.2020.173539. Epub 2020 Sep 9. PMID: 32918874.
1: Rokhlin OW, Guseva NV, Taghiyev AF, Glover RA, Cohen MB. KN-93 inhibits androgen receptor activity and induces cell death irrespective of p53 and Akt status in prostate cancer. Cancer Biol Ther. 2010;9(3):224-235. doi:10.4161/cbt.9.3.10747
2: An P, Zhu JY, Yang Y, et al. KN-93, a specific inhibitor of CaMKII inhibits human hepatic stellate cell proliferation in vitro. World J Gastroenterol. 2007;13(9):1445-1448. doi:10.3748/wjg.v13.i9.1445
3: Gao L, Blair LA, Marshall J. CaMKII-independent effects of KN93 and its inactive analog KN92: reversible inhibition of L-type calcium channels. Biochem Biophys Res Commun. 2006;345(4):1606-1610. doi:10.1016/j.bbrc.2006.05.066
4: Rezazadeh S, Claydon TW, Fedida D. KN-93 (2-[N-(2-hydroxyethyl)]-N-(4-methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzylamine), a calcium/calmodulin-dependent protein kinase II inhibitor, is a direct extracellular blocker of voltage-gated potassium channels. J Pharmacol Exp Ther. 2006;317(1):292-299. doi:10.1124/jpet.105.097618
5: Anderson ME, Braun AP, Wu Y, et al. KN-93, an inhibitor of multifunctional Ca++/calmodulin-dependent protein kinase, decreases early afterdepolarizations in rabbit heart. J Pharmacol Exp Ther. 1998;287(3):996-1006.
6: Sumi M, Kiuchi K, Ishikawa T, et al. The newly synthesized selective Ca2+/calmodulin dependent protein kinase II inhibitor KN-93 reduces dopamine contents in PC12h cells. Biochem Biophys Res Commun. 1991;181(3):968-975. doi:10.1016/0006-291x(91)92031-e
